In a Phase Ib trial, the combination of the NEO-PV-01 neoantigen vaccine with pembrolizumab-enhanced neoantigen-specific CD4+ and CD8+ T cell responses and improved clinical outcomes in advanced melanoma patients [62]. Here, CD8A is linked to melanoma.